Epicrispr wins $8M CIRM grant for FSHD gene therapy trial
What's the deal? Epicrispr Biotechnologies has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM)Dealroom has a profile for this one. Try Dealroom → to fund its ongoing first-in-human trial of EPI-321, a one-time epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD).
What does the company do? The clinical-stage biotech develops epigenetic therapies that silence disease-driving genes without altering DNA. EPI-321 is designed to durably suppress DUX4, the genetic driver of FSHD, a progressive neuromuscular disease with no approved treatment.
Why it stands out: The award, made through CIRM's Clinical Trial Stage Projects program, ranks among the larger grants in US healthcare — above roughly 94% of comparable grant rounds in the sector.
Why now? The grant follows six-month data from Epicrispr's Phase 1/2 study, presented at the World Muscle Society congress, showing gains in lean muscle volume and strength after a single dose. Those results are early and from a small open-label cohort — not yet proof of clinical benefit.
The non-dilutive funding also builds on a $90 million Series C the company closed in August to push EPI-321 toward pivotal testing.
What they're saying: "This $8 million award from CIRM represents important validation of our innovative epigenetic editing approach," said chief executive officer Amber Salzman. CIRM science officer Maria Chiuchiolo called FSHD "a devastating progressive neuromuscular disease with no approved disease-modifying treatments."
What could go wrong? The grant does not resolve open questions on safety, durability, and efficacy. One trial case involved severe liver enzyme elevation, and rivals are circling — Altay TherapeuticsDealroom has a profile for this one. Try Dealroom → raised $37 million for an oral DUX4 inhibitor.
The signal: State-backed, non-dilutive capital is flowing to one-time genetic therapies targeting diseases with no approved options. For Epicrispr, the award is validation; whether EPI-321 becomes the first disease-modifying FSHD therapy still rests on clinical data to come.
Read more: AP News
Image credit: Epicrispr Biotechnologies
